1-20 of 25
Keywords: L-Dopa
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Eur Neurol (2009) 62 (2): 114–119.
Published Online: 12 June 2009
... bradykinesia, which we validated by assessing the therapeutic effects of L -dopa and STN-HFS in PD patients (fig. 1 ). The aim of this study was to examine whether the simple tapping task can be subdivided into a proximal and a distal component, and whether these are modulated differentially by therapeutic...
Journal Articles
Eur Neurol (1994) 34 (Suppl. 3): 17–19.
Published Online: 27 February 2008
...Sadako Kuno L-Dopa pioneered the symptomatic therapy of Parkinson’s disease. While this treatment proved effective in the treatment of parkinsonian akinesia, rigidity and tremor, prolonged L-dopa treatment was often noted to result in dyskinesia, psychosis and ‘on-off phenomena. This increasing...
Journal Articles
Journal Articles
Journal Articles
Eur Neurol (1990) 30 (Suppl. 1): 31–40.
Published Online: 12 February 2008
... to abnormalities in the DA neuronal system. IDPN-induced dyskinesia was enhanced by administration of L-dopa, which increases DA concentration, but was completely inhibited by ceruletide, which inhibits DA release. The dyskinesia was also inhibited by sulpiride, a central antagonist of D2 DA receptors...
Journal Articles
Eur Neurol (1987) 27 (1): 35–38.
Published Online: 05 February 2008
...M.A. Bédard; J. Montplaisir; R. Godbout Five narcoleptic patients presenting periodic movements in sleep were investigated during treatment with L-dopa administered together with a decarboxylase inhibitor. One of these patients was also treated with gamma-hydroxybutyrate and zimelidine...
Journal Articles
Eur Neurol (1988) 28 (5): 291–294.
Published Online: 05 February 2008
...Fumiko Ishizaki; Seiho Nishikawa In 21 parkinsonian patients, we investigated the contents of blood serotonin (5HT) and benzylamine oxidase (BzAO) before and during L-dopa therapy. Then, we studied the patients prospectively, and evaluated the relationship between 5HT and BzAO and the clinical...
Journal Articles
Eur Neurol (1982) 21 (4): 227–234.
Published Online: 30 January 2008
...T.C.A.M. van Woerkom; J.M. Minderhoud; T. Gottschal; G. Nicolai Results of treatment with L-dopa and/or physostigmine of patients with severe head injuries were examined and discussed. This treatment given to patients still unconscious a long period after trauma resulted in clinical improvement...
Journal Articles
Eur Neurol (1980) 19 (1): 43–48.
Published Online: 29 January 2008
...M. Streifler; E. Avrami; J.M. Rabey Sebum secretion was studied in 14 parkinsonian patients before and after 3 months of treatment with L -dopa. An abnormality of sebum secretion was shown to exist in parkinsonism. In 7 patients, successfully treated with L -dopa, sebum secretion diminished and its...
Journal Articles
Eur Neurol (1981) 20 (2): 118–124.
Published Online: 29 January 2008
... of the patients were studied again after 2 weeks of treatment with L-dopa + decarboxylase inhibitor. HVA excretion increased 20-fold while c-AMP excretion decreased 9% (p less 0.05). The reduction in the c-AMP excretion was observed only in the subgroups with akinesia or rigidity as the main symptom (p less 0.025...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Eur Neurol (1977) 15 (1): 34–39.
Published Online: 25 January 2008
... greater impairment in dysarthria and pyramidal tract indexes of patients with thalamotomy. L -Dopa and carbidopa therapy failed to significantly improve speech in any group. 24 11 1975 7 01 1976 25 1 2008 © 1977 S. Karger AG, Basel 1977 Copyright / Drug Dosage / Disclaimer...
Journal Articles
Journal Articles
Journal Articles
Eur Neurol (1972) 8 (6): 339–351.
Published Online: 24 January 2008
...M.R. Caccia; G. Avanzini; S. Negri The following problems were considered: (1) nature of the asynchronous response in the glabellar reflex (GR); (2) changes in the GR parameters induced by L-dopa; (3) changes induced by the drug in the masseter muscle silent period (SP); (4) meaning...
Journal Articles
Eur Neurol (1972) 7 (4): 228–240.
Published Online: 23 January 2008
...U.K. Rinne; V. Sonninen; T. Siirtola Treatment of Parkinson’s disease with amantadine and L-dopa was studied in 82 patients. A double-blind cross-over trial with 38 patients showed a significant benefit with 200 mg of amantadine daily. During non-blind treatment with 300 mg of amantadine for 2–4...